Key Highlights
- Arcturus Therapeutics shares are trading at $14.18 in pre-market activity, up 6.62% from Wednesday's close of $13.30.
- The company reported encouraging interim Phase 2 results for ARCT-810 in ornithine transcarbamylase deficiency, showing the therapy was generally safe and well tolerated.
- Arcturus introduced LUNAR 2.0, a next-generation mRNA delivery platform showing greater than 30-fold higher protein expression in non-human primate studies.
- The company also announced an agreement to acquire myNEO, an AI discovery company, to strengthen its mRNA design and target identification capabilities.
Interim Trial Data Shows Encouraging Biomarker Activity
Arcturus Therapeutics (NASDAQ:ARCT) shares are rising pre-market after the company reported encouraging interim Phase 2 results from ARCT-810 in patients with ornithine transcarbamylase deficiency, a rare inherited disorder affecting the liver's ability to remove toxic ammonia from the blood. The therapy was generally safe and well tolerated, reduced or maintained first morning fasting ammonia within the normal range even during periods of increased protein intake, and reduced glutamine levels, with some participants achieving normal range values.
New LUNAR 2.0 Platform Unlocks Additional Disease Targets
Alongside the trial update, the company introduced LUNAR 2.0, its next-generation mRNA delivery platform incorporating improved lipids and an enhanced formulation process. In non-human primate studies, the new platform demonstrated a 40-fold improvement over the prior generation in expressing a reference protein, and 38-fold greater potency than the lipid used in ARCT-810 when expressing the OTC enzyme. The company said the platform opens up new therapeutic opportunities previously considered inaccessible, including phenylketonuria and gout, and plans to integrate a next-generation candidate built on the new platform into its ongoing OTC deficiency study by year-end, following favorable regulatory feedback from the FDA.
Acquisition Adds AI-Driven Drug Design Capability
Arcturus also announced a definitive agreement to acquire myNEO, an AI discovery company, in a deal expected to close in October. The Acquisition is intended to improve the quality of the company's mRNA designs and enhance its target identification capabilities, building on a working relationship between the two companies since 2024. Arcturus is a San Diego-based messenger RNA medicines company focused on liver and respiratory therapeutics, and previously developed the world's first approved self-amplifying mRNA COVID vaccine.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...